Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.48 USD | +1.76% | -0.62% | -3.29% |
Apr. 18 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
Apr. 10 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.29% | 714M | |
-0.49% | 103B | |
+3.54% | 96.73B | |
+0.90% | 21.31B | |
-15.84% | 21.21B | |
-6.26% | 18.79B | |
-42.14% | 16.37B | |
-21.63% | 13.68B | |
+7.29% | 13.44B | |
+24.08% | 10.98B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- Credit Suisse Lowers ALX Oncology Holdings' Price Target to $41 from $53, Maintains Outperform Rating